The critical need for alternative antiretroviral formulations, and obstacles to their development

Susan Swindells; Charles Flexner; Courtney V. Fletcher; Jeffrey M. Jacobson

doi:10.1093/infdis/jir370

The critical need for alternative antiretroviral formulations, and obstacles to their development

Susan Swindells, Charles Flexner, Courtney V. Fletcher, Jeffrey M. Jacobson

School of Medicine

Research output: Contribution to journal › Article › peer-review

Original language	English (US)
Pages (from-to)	669-674
Number of pages	6
Journal	Journal of Infectious Diseases
Volume	204
Issue number	5
DOIs	https://doi.org/10.1093/infdis/jir370
State	Published - Sep 1 2011

ASJC Scopus subject areas

Immunology and Allergy
Infectious Diseases

Access to Document

10.1093/infdis/jir370

Cite this

@article{0525316417ca4b339630129aec33e803,

title = "The critical need for alternative antiretroviral formulations, and obstacles to their development",

author = "Susan Swindells and Charles Flexner and Fletcher, {Courtney V.} and Jacobson, {Jeffrey M.}",

note = "Funding Information: Potential conflicts of interest: S. S. has received research grants or contracts from or has been a consultant for Abbott Pharmaceuticals, Bavarian Nordic, GlaxoSmithKline, Novartis Pharmaceuticals Corporation, Pfizer, and Tibotec Therapeutics. C. V. F. has served as an ad hoc consultant to Bristol-Myers Squibb and Merck, Inc, and received honorarium payments for such participation. C. F. has received grant support from GlaxoSmithKline for research unrelated to this manuscript; has served as a consultant to Bristol-Myers Squibb, Boehringer-Ingelheim, GlaxoSmithKline, Merck, Roche, Schering-Plough, and Tibotec; and has received honoraria for presentations at meetings sponsored in part by Abbott Laboratories. J. J. has received research grants from Progenics and Tanox (now Taimed). Funding Information: This work was supported by the AIDS Clinical Trials Group funded by the National Institute of Allergy and Infectious Diseases (grants U01 AI68636 and AI068634; AI69450 to S. S.; AI069465 to C. F.; and P01 AI074340, UOI AI68636, and UOI AI68632 to C. V. F.); and the National Institute of Drug Abuse (P01 DA028555-01A1 to S. S. and C. V. F.).",

year = "2011",

month = sep,

day = "1",

doi = "10.1093/infdis/jir370",

language = "English (US)",

volume = "204",

pages = "669--674",

journal = "Journal of Infectious Diseases",

issn = "0022-1899",

publisher = "Oxford University Press",

number = "5",

}

TY - JOUR

T1 - The critical need for alternative antiretroviral formulations, and obstacles to their development

AU - Swindells, Susan

AU - Flexner, Charles

AU - Fletcher, Courtney V.

AU - Jacobson, Jeffrey M.

N1 - Funding Information: Potential conflicts of interest: S. S. has received research grants or contracts from or has been a consultant for Abbott Pharmaceuticals, Bavarian Nordic, GlaxoSmithKline, Novartis Pharmaceuticals Corporation, Pfizer, and Tibotec Therapeutics. C. V. F. has served as an ad hoc consultant to Bristol-Myers Squibb and Merck, Inc, and received honorarium payments for such participation. C. F. has received grant support from GlaxoSmithKline for research unrelated to this manuscript; has served as a consultant to Bristol-Myers Squibb, Boehringer-Ingelheim, GlaxoSmithKline, Merck, Roche, Schering-Plough, and Tibotec; and has received honoraria for presentations at meetings sponsored in part by Abbott Laboratories. J. J. has received research grants from Progenics and Tanox (now Taimed). Funding Information: This work was supported by the AIDS Clinical Trials Group funded by the National Institute of Allergy and Infectious Diseases (grants U01 AI68636 and AI068634; AI69450 to S. S.; AI069465 to C. F.; and P01 AI074340, UOI AI68636, and UOI AI68632 to C. V. F.); and the National Institute of Drug Abuse (P01 DA028555-01A1 to S. S. and C. V. F.).

PY - 2011/9/1

Y1 - 2011/9/1

UR - http://www.scopus.com/inward/record.url?scp=80051753353&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80051753353&partnerID=8YFLogxK

U2 - 10.1093/infdis/jir370

DO - 10.1093/infdis/jir370

M3 - Article

C2 - 21788451

AN - SCOPUS:80051753353

VL - 204

SP - 669

EP - 674

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - 5

ER -